NICE blow for Novartis' Gilenya could be good news for Biogen
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has again published draft guidance declining to recommend Novartis' Gilenya (fingolimod) for treating relapsing-remitting multiple sclerosis (RRMS). It claims the drug would not be cost-effective.
You may also be interested in...
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.